Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Equity Average (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Equity Average for 5 consecutive years, with $62.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average rose 493.56% year-over-year to $62.7 million, compared with a TTM value of $62.7 million through Dec 2025, up 493.56%, and an annual FY2025 reading of $12.3 million, down 61.06% over the prior year.
  • Equity Average was $62.7 million for Q4 2025 at Aligos Therapeutics, down from $86.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $200.9 million in Q4 2021 and bottomed at $10.6 million in Q4 2024.
  • Average Equity Average over 5 years is $102.7 million, with a median of $86.8 million recorded in 2025.
  • The sharpest move saw Equity Average crashed 85.62% in 2024, then surged 493.56% in 2025.
  • Year by year, Equity Average stood at $200.9 million in 2021, then tumbled by 43.77% to $113.0 million in 2022, then crashed by 34.97% to $73.5 million in 2023, then plummeted by 85.62% to $10.6 million in 2024, then soared by 493.56% to $62.7 million in 2025.
  • Business Quant data shows Equity Average for ALGS at $62.7 million in Q4 2025, $86.8 million in Q3 2025, and $109.2 million in Q2 2025.